AI-Designed Drug Shows Biological Age Reversal in Clinical Trial

A drug candidate discovered and designed entirely through artificial intelligence has demonstrated measurable reversal of biological age in human patients, according to a study published in Nature Biotechnology. The research represents the first clinical evaluation of a molecule created from scratch by AI—rather than a repurposed existing drug—that shows geroprotective effects.

Insilico Medicine reported that rentosertib, developed for idiopathic pulmonary fibrosis (IPF), reduced predicted biological age by approximately three to four years at peak effect, with one aging clock showing up to six years of reversal. The findings emerged from analysis of a Phase IIa trial involving 42 participants, as first reported by News Medical.

How the Drug Was Discovered

Insilico's AI platform identified TNIK as a novel target implicated in both aging and fibrosis. The company's generative chemistry system, Chemistry42, then designed rentosertib to inhibit TNIK. The program moved from target identification to preclinical candidate in approximately 18 months—a timeline that would be difficult to achieve through traditional drug discovery methods.

The Phase IIa trial, conducted in 2025 for IPF, met its primary safety endpoint. Patients receiving 60 mg once daily showed mean improvement in forced vital capacity (FVC) of 98.4 mL, compared to a decline of 20.3 mL in the placebo group. FVC measures lung function and typically declines 20-50 mL per year in healthy individuals over 65.

Six Independent Clocks Confirm Age Reversal

Researchers from Harvard Medical School, Stanford University, The Broad Institute, and other institutions analyzed serum proteome profiles across 2,841 proteins. They applied six independently developed proteomic aging clocks—ProtAge, OrganAge, PAC, ipfP3GPT, and PAOPAC—each built using different methodologies and training data.

All six models consistently showed biological age reduction in rentosertib-treated patients compared to placebo. The strongest effect appeared at week four in participants receiving 30 mg twice daily. Notably, the dose producing the greatest age-reversal signal differed from the dose showing the most lung function improvement, suggesting the geroprotective activity operates independently of respiratory benefits.

The drug suppressed key drivers of cellular senescence and downregulated growth-factor signaling pathways associated with accelerated aging, including RTK-PI3K and RAS-ERK.

Why It Matters

This study establishes a framework for embedding aging biomarkers into standard disease-focused clinical trials, potentially accelerating the discovery of longevity therapeutics by years or decades. Rather than waiting for post-approval repurposing studies, pharmaceutical companies could evaluate geroprotective effects during initial development. The approach also validates AI's capacity to discover novel drug targets and design molecules that address fundamental aging biology—not just individual age-related diseases.

Insilico has deposited all research data at the China National Center for Bioinformation and published the analysis pipeline as open-source code on GitHub. Rentosertib has advanced to Phase III trials for IPF.

The company reported $106 million in revenue for the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year. Insilico nominated nine development candidates in the first nine months of 2026 and announced collaborations with a cumulative contract value of approximately $11 billion since 2021.

Details of the research were first reported by News Medical and will be presented at the Nature conference on AI in healthcare at Sorbonne University on September 8, 2026.